RE: Bristol Myers wins a megablockuster bet with TYK2 FDA approval — and there's a big bonus for the lab11 Sep 2022 15:40
As the lead developer, Sareum is likely to receive a much higher proportion of any licensing deal it secures for its TYK2/JAK1 inhibitors. The Company continues to actively engage with potential partners with a view to securing commercial licences for this programme. Optimising the time to strike a deal is a delicate balance of funding and risk management. The further Sareum takes its programme the higher the potential rewards, but also the higher the risk of clinical failure. This is mitigated to some extent by Sareum having two molecules in development. The completion of SDC-1801’s pre-clinical work in the coming months is the next milestone to look out for. A solid pre-clinical package will give Sareum optionality. It does not have to divest all of the crown jewels now particularly if a deal is not front end loaded. Having a second candidate also gives Sareum room for flexibility.
However, should Sareum successfully take one or both candidates into, or to the end of Phase 1, the returns promise to generate a significant multiple of the current market capitalisation of £60.5m as at the close of business on 2 February. The programme has the potential to generate one or more blockbusters, and positive news flow from the Covid-19 project will do no harm in focussing partner and investor attention on these exciting molecules.
https://www.google.co.uk/amp/s/masterinvestor.co.uk/equities/stocks-in-focus-sareum-holdings/amp/
Sign In
Follow the stocks
